Zacks Research Issues Negative Outlook for Hologic Earnings

Hologic, Inc. (NASDAQ:HOLX) – Equities researchers at Zacks Research cut their Q1 2025 EPS estimates for Hologic in a report released on Tuesday, December 31st. Zacks Research analyst R. Department now anticipates that the medical equipment provider will post earnings of $1.01 per share for the quarter, down from their prior estimate of $1.02. The consensus estimate for Hologic’s current full-year earnings is $4.28 per share. Zacks Research also issued estimates for Hologic’s Q2 2025 earnings at $1.06 EPS, FY2025 earnings at $4.28 EPS, Q1 2026 earnings at $1.12 EPS, Q2 2026 earnings at $1.14 EPS, Q4 2026 earnings at $1.20 EPS, FY2026 earnings at $4.63 EPS, Q1 2027 earnings at $1.12 EPS and FY2027 earnings at $4.99 EPS.

A number of other analysts also recently issued reports on HOLX. UBS Group lifted their price objective on shares of Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Citigroup downgraded Hologic from a “buy” rating to a “neutral” rating and dropped their price target for the company from $95.00 to $85.00 in a research note on Tuesday, October 1st. Leerink Partners lowered their price objective on Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Wolfe Research assumed coverage on Hologic in a report on Friday, December 13th. They issued a “peer perform” rating on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $90.00 target price on shares of Hologic in a report on Thursday, December 19th. Six analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $89.50.

Hologic Stock Performance

Shares of NASDAQ:HOLX opened at $73.19 on Friday. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. The company has a market capitalization of $16.61 billion, a price-to-earnings ratio of 21.98, a P/E/G ratio of 2.32 and a beta of 0.97. The firm’s 50 day simple moving average is $76.72 and its 200 day simple moving average is $78.49. Hologic has a fifty-two week low of $70.36 and a fifty-two week high of $84.67.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting the consensus estimate of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. During the same period in the previous year, the business posted $0.89 EPS. The company’s quarterly revenue was up 4.5% compared to the same quarter last year.

Institutional Trading of Hologic

Hedge funds and other institutional investors have recently bought and sold shares of the company. Andra AP fonden grew its position in Hologic by 224.5% during the 2nd quarter. Andra AP fonden now owns 95,400 shares of the medical equipment provider’s stock worth $7,083,000 after acquiring an additional 66,000 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Hologic by 17.9% during the third quarter. GAMMA Investing LLC now owns 3,832 shares of the medical equipment provider’s stock valued at $312,000 after purchasing an additional 582 shares during the period. Janus Henderson Group PLC boosted its stake in shares of Hologic by 2.9% during the third quarter. Janus Henderson Group PLC now owns 28,776 shares of the medical equipment provider’s stock valued at $2,344,000 after purchasing an additional 800 shares during the period. Quest Partners LLC boosted its stake in shares of Hologic by 56.1% during the second quarter. Quest Partners LLC now owns 41,492 shares of the medical equipment provider’s stock valued at $3,081,000 after purchasing an additional 14,914 shares during the period. Finally, Versor Investments LP purchased a new stake in shares of Hologic during the third quarter valued at approximately $1,677,000. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Insider Buying and Selling

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares of the company’s stock, valued at $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.75% of the stock is currently owned by insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.